Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapy

@inproceedings{Owens2017FutureCA,
  title={Future challenges and therapeutic opportunities in type 2 diabetes: Changing the paradigm of current therapy},
  author={David R. Owens and Laureline Monnier and Anthony Desmond Barnett},
  booktitle={Diabetes, obesity & metabolism},
  year={2017}
}
Most algorithms for type 2 diabetes mellitus (T2DM) do not recommend treatment escalation until glycated haemoglobin (HbA1c) fails to reach the recommended target of 7% (53 mmol/mol) within approximately 3 months on any treatment regimen ("treat to failure"). Clinical inertia and/or poor adherence to therapy contribute to patients not reaching glycaemic targets when managed according to this paradigm. Clinical inertia exists across the entire spectrum of anti-diabetes therapies, although it is… CONTINUE READING
8
Twitter Mentions

References

Publications referenced by this paper.
SHOWING 1-10 OF 100 REFERENCES

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

  • Nature Reviews Endocrinology
  • 2012
VIEW 6 EXCERPTS
HIGHLY INFLUENTIAL

When oral agents fail: practical barriers to starting insulin

  • International Journal of Obesity
  • 2002
VIEW 5 EXCERPTS
HIGHLY INFLUENTIAL

Similar Papers